Serial No. : 10/551,999 I.A. Filing Date : April 1, 2004

Page: 2

## **LISTING OF THE CLAIMS**

1. (Cancelled)

- 2. (Cancelled)
- 3. (Cancelled)
- 4. (Currently Amended) A method of treating functional constipation or C-IBS, in a warm-blooded animal in need of such treatment, which method comprises administering to said animal an effective amount of an IBAT inhibitor selected from:
  - $1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-\{(R-)-\alpha-[N-((R)-1-carboxy-2-methylthio-ethyl)carbamoyl]-4-hydroxybenzyl\} carbamoylmethoxy)-2,3,4,5-tetrahydro-$
  - 1,2,5-benzothiadiazepine;
  - 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-
  - 1,2,5-benzothiadiazepine;

  - methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-
  - 1,2,5-benzothiadiazepine;

  - $carboxybutyl) carbamoyl] 4-hydroxybenzyl\} carbamoylmethoxy) 2, 3, 4, 5-tetra hydro-polycomethological carbana and the state of th$
  - 1,2,5-benzothiadiazepine;
  - 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-
  - carboxypropyl)carbamoyl]benzyl) carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-
  - benzothiadiazepine;
  - 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-
  - carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-
  - benzothiadiazepine;

Serial No. : 10/551,999 I.A. Filing Date : April 1, 2004

Page: 3

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8 (*N*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)-α-[(*N*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((R)-1-carboxy-2-methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-2-hydroxy-1-carboxyethyl)carbamoyl]propyl}carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

 $\frac{1,1-\text{dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-}(N-\{(R)-\alpha-[N-\{(S)-1-[N-((S)-2-hydroxy-1-carboxyethyl)carbamoyl]propyl\}carbamoyl]benzyl\}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;}$ 

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahdro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-((R)- $\alpha$ -carboxy-4-hydroxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

Attorney Docket No. 23854-0004US1

Inventor(s) : Hasse Roland Abrahamsson, et al.

amide formed on an available carboxy thereof.

Serial No. : 10/551,999 I.A. Filing Date : April 1, 2004

Page : 4

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N- $\{(R)$ - $\alpha$ -[N- $\{(2$ -(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl $\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N- $\{(R)$ - $\alpha$ -[N- $\{(2$ -(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexl)carbamoyl]-4-hydroxybenzyl $\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; or a pharmaceutically acceptable salt, solvate, solvate of such a salt, or an *in vivo* hydrolysable ester formed on an available carboxy or hydroxy or an *in vivo* hydrolysable

- 5. (Cancelled)
- 6. (Cancelled)
- 7. (Cancelled)
- 8. (Previously Presented) The method according to claim 4 or claim 10 for the treatment of functional constipation.
- 9. (Previously Presented) The method according to claim 4 or claim 10 for the treatment of C-IBS.
- 10. (Currently Amended) A method of treating functional constipation or C-IBS, in a warm-blooded animal in need of such treatment, which method comprises administering to said animal an effective amount of an IBAT inhibitor selected from:
  - 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-[N'-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

Serial No. : 10/551,999 I.A. Filing Date : April 1, 2004

Page: 5

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N- $\{(R)-\alpha-[N'-(carboxymethyl)carbamoyl]-4-hydroxybenzyl\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-[N'-(2-sulphoethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-[N'-(2-sulphoethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N{(R)- $\alpha$ -[N'-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8- $(N-\{(R)-\alpha-[N'-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro,-5-benzothiazepine:

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N- $\{R\}$ )- $\alpha$ -[N'-(2-carboxyethyl)carbamoyl]benzyl $\{R\}$  carbamoylmethoxy $\{R\}$ -2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N)- $\{(R)$ - $\alpha$ -[N'-(2-carboxyethyl)carbamoyl]-4-hydroxybenzyl $\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

 $1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-\{(R)-\alpha-[N'-(5-carboxypentyl)carbamoyl]benzyl\} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;$ 

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N- $\{(R)-\alpha-[N'-(2-carboxyethyl)carbamoyl]benzyl\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N- $\{\alpha-[N'-(2-\text{sulphoethyl})\text{carbamoyl}]-2-\text{fluorobenzyl}\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1-,5-benzothiazepine;

Serial No. : 10/551,999 I.A. Filing Date : April 1, 2004

Page: 6

1,1-dioxo-3-butyl-5-ethyl-phenyl-7-methylthio-8-(N- $\{(R)-\alpha-[N'-\{(R)-1-[N''-\{R)-(2-N''-\{(R)-1-[N''-\{R)-(2-N''-\{(R)-1-[N''-\{(R)-1-[N''-\{R)-(2-N''-\{(R)-1-[N''-1-[N''-$ 

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N- $\{(R)-\alpha-[N'-(R)-2-hydroxy-1-(carboxymethyl)carbamoyl]-benzyl\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $\{N-[(R)-\alpha-(N'-\{(R)-1-[N''(R)(2-hydroxy-1-carboxyethyl)carbamoyl]-2-hydroxyethyl\}carbamoyl)benzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;$ 

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N- $\{\alpha-[N'-(carboxymethyl)carbamoyl]benzyl\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3ethyl-5-phenyl-7-methylthio-8-(N- $\{\alpha-[N'-((ethoxy)(methyl)phosphorylmethyl)carbamoyl]benzyl\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

 $1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-\{N-[(R)-\alpha-(N'-\{2-[(hydroxy)(methyl)phosphoryl]ethyl\} carbamoyl)benzyl]carbamoylmethoxy\}-2,3,4,5-tetrahydro-1,5-benzothiazepine;$ 

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N- $\{(R)-\alpha-[N'-(2-methylthio-1-carboxyethyl)carbamoyl]benzyl\}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;$ 

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $\{N-[(R)-\alpha-(N'-\{2-[(methyl)(ethyl)phosphoryl]ethyl\}$  carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

Serial No. : 10/551,999 I.A. Filing Date : April 1, 2004

Page: 7

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $\{N-[(R)-\alpha-(N'-\{2-[(methyl)(hydroxy)phosphoryl]ethyl\}$  carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N- $\{(R)$ - $\alpha$ -[(R)-N'-(2-methylsulphinyl-1-carboxyethyl)carbamoyl]benzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methoxy-8-[N- $\{(R)-\alpha$ -[N'-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N- $\{(R)$ - $\alpha$ -[N'-(2-(S)-3-(R)-4-(R)-5-(R)-1,1-dioxo-1,1-di

2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N- $\{(R)-\alpha-[N'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)$ carbamoyl]benzyl $\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

 $1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-\{(R)-\alpha-[N'-((S)-1-carbamoyl-2-hydroxyethyl)carbamoyl]benzyl\} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazopine;$ 

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N- $\{(R)-\alpha-[N'-(hydroxycarbomoyl-methyl)carbamoyl]benzyl\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1-,5-benzothiazepine; 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[N-((R)- $\alpha$ - $\{N'[2-(N'-pyrimidin-2-ylureido)ethyl]carbamoyl\}$  benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[N-((R)- $\alpha$ -{N'-[2-(N'-pyridin-2-ylureido)ethyl]carbamoyl}benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N- $\{(R)-\alpha-[N'-(1-3-butoxycarbonylpiperidin-4-ylmethyl)carbamoyl]$  benzyl $\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

Serial No. : 10/551,999 I.A. Filing Date : April 1, 2004

Page: 8

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N- $\{(R)-\alpha-[N'-(2,3-dihydroxypropyl)carbamoyl]benzyl\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[N-((R)- $\alpha$ -(N'-[2-(3,4-dihydroxypheny1)-2-methoxyethyl] carbamoyl} benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio- $8(N-\{(R)-\alpha-[N-(2-aminoethyl)carbamoyl]benzyl\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N- $\{(R)$ - $\alpha$ -[N'-(piperidin-4-ylmethyl)carbamoyl]benzyl $\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine; and

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N- $\{(R)$ - $\alpha$ -[N'-(2-N,N-dimethylaminosulphamoylethyl)carbamoyl]benzyl $\}$  carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt, or an *in vivo* hydrolysable ester formed on an available carboxy or hydroxyl or an *in vivo* hydrolysable amide formed on an available carboxy thereof.